Azenta Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition expands European presence, leverages automation synergies, and positions for scalable growth in life sciences. Minimal CapEx is required, with commercial investments driving future revenue and margin expansion. 2026 will be dilutive, but accretive from 2027.
-
The company is executing a turnaround with a focus on operational excellence, margin expansion, and commercial effectiveness. Key initiatives include decentralization, sales force transformation, and ABS-driven process improvements, with strong free cash flow and EBITDA growth targeted over the next three years.
-
Q1 revenue was $149M, up 1% reported but down 1% organically, with margin pressures from quality issues and regional mix. FY2026 guidance for 3%-5% organic growth and 300 bps EBITDA margin expansion reaffirmed, with acceleration expected in the second half as investments and market conditions improve.
-
A transformative year featured strong cash reserves, margin expansion, and a $250M share repurchase. Four shareholder proposals, including board elections and an equity plan amendment, were all approved. Strategic plans include divesting B Medical by March 2026.
Fiscal Year 2025
-
A decentralized structure and operational excellence are driving growth, with biorepositories and gene synthesis regionalization as key initiatives. Financial targets include doubling EBITDA and reaching $700M-$750M revenue by 2028, supported by disciplined capital allocation and a robust M&A pipeline.
-
Fiscal 2025 saw 3% core growth and 310 bps margin expansion, with strong cash flow and a robust balance sheet. Guidance for 2026 targets 3%-5% organic growth, 300 bps EBITDA margin expansion, and improved free cash flow, despite macro headwinds and a slow Q1 start.
-
Q3 2025 revenue was flat year-over-year at $144 million, with adjusted EBITDA margin expanding 260 basis points to 12.3%. Guidance for 3%-5% organic revenue growth and 300 basis points of margin expansion was reaffirmed, supported by strong NGS and Sample Storage performance and robust cash reserves.
-
Q2 2025 saw 6% organic revenue growth and 400 bps adjusted EBITDA margin expansion, with strong performance in both sample management and multiomics. Guidance for 2025 is reaffirmed, with countermeasures in place for NIH funding and tariff headwinds.
-
Management expects only a 2% revenue risk from academic/government funding in 2025, with new opportunities as institutions outsource core lab functions. Storage as a service and automation drive growth, while China and biopharma markets remain robust. Analyst day is planned for June.
-
Q1 2025 saw 4% organic revenue growth and a 400 bps adjusted EBITDA margin expansion, with strong performance in both SMS and Multiomics. Guidance for 2025 is reiterated, with 3%-5% organic growth and 300 bps margin expansion, while capital allocation focuses on growth and operational efficiency.
Fiscal Year 2024
-
New leadership is driving a turnaround with a focus on lean operations, cost reduction, and portfolio simplification, starting with the divestiture of B Medical. Enhanced governance, unified incentives, and targeted capital allocation aim to improve margins and position the business for growth.
-
Q4 and FY2024 results met guidance with $656M revenue and strong margin expansion, driven by SMS and multi-omics growth. Guidance for FY2025 is 3%-5% organic revenue growth and 300 bps EBITDA margin expansion, with B Medical divestiture expected in 1H 2025.
-
Q3 2024 saw 5% organic revenue growth and significant margin expansion, driven by strong execution, cost-saving initiatives, and robust performance across all segments. Guidance was lowered due to timing shifts, but margin and EPS outlooks were raised, with continued confidence in long-term growth.
-
Leadership transition is underway as the company leverages a decade-long transformation into life sciences, focusing on integration, margin improvement, and growth in China. Financial outlook is strong with a Q4 ramp, robust storage and consumables growth, and a $40M cross-selling backlog. Capital allocation remains disciplined, prioritizing share repurchases and strategic M&A.